Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist

• Status: Completed
• Trial end date: 2013-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

The aim of our study is to define the optimal ovarian stimulation protocol concerning PGD and for this reason we plan a randomized controlled trial (RCT) comparing gonadotropin-releasing hormone (GnRH) agonist protocol versus GnRH antagonist protocol. The follicle stimulating hormone (FSH) preparation in both arms will be highly purified FSH (Menopur®).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Universitair Ziekenhuis Brussel
• Treatments: Buserelin; Cetrorelix; Chorionic Gonadotropin; Deslorelin; Ganirelix; Menotropins; Progesterone; Prolactin Release-Inhibiting Factors; Triptorelin Pamoate

Criteria

Inclusion Criteria:

• ≤ 39 years the day of oocyte retrieval

• BMI ≤ 29

• cycle rank 1

• menstrual cycle 25-36 days

• PGD or preimplantation genetic screening (PGS) requested

• ICSI

• Single embryo transfer (SET) on day 5

Exclusion Criteria:

• Polycystic Ovary Syndrome (PCOS) (according Rotterdam criteria)

• Hormonal disturbances

• Endometriosis grade III and IV